{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:47:10Z","timestamp":1789948030705,"version":"4.0.1"},"reference-count":8,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2007,8,13]],"date-time":"2007-08-13T00:00:00Z","timestamp":1186963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2007,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose\u2010finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose\u2010escalation\/de\u2010escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g\/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose\u2010response. In conclusion, SPB at 12 to 15 g\/day appears to be safe and well\u2010tolerated in human HD. \u00a9 2007 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.21632","type":"journal-article","created":{"date-parts":[[2007,8,13]],"date-time":"2007-08-13T18:46:47Z","timestamp":1187030807000},"page":"1962-1964","source":"Crossref","is-referenced-by-count":77,"title":["Sodium phenylbutyrate in Huntington's disease: A dose\u2010finding study"],"prefix":"10.1002","volume":"22","author":[{"given":"Penelope","family":"Hogarth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Lovrecic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Krainc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,10,26]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/35099568"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M410210200"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0437870100"},{"key":"e_1_2_6_6_2","first-page":"2292","article-title":"A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies","volume":"7","author":"Gilbert J","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000223353.34006.54"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddh131"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504921102"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.21632","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.21632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:49:20Z","timestamp":1760968160000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.21632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,15]]},"references-count":8,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2007,10,15]]}},"alternative-id":["10.1002\/mds.21632"],"URL":"https:\/\/doi.org\/10.1002\/mds.21632","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,15]]}}}